Suppr超能文献

三种贝特类衍生物和两种HMG-CoA还原酶抑制剂对原发性高胆固醇血症患者血浆纤维蛋白原水平的影响。

Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.

作者信息

Branchi A, Rovellini A, Sommariva D, Gugliandolo A G, Fasoli A

机构信息

Institute of Internal Medicine and Medical Physiopathology, University of Milan, Italy.

出版信息

Thromb Haemost. 1993 Aug 2;70(2):241-3.

PMID:8236126
Abstract

In order to evaluate the effects of hypocholesterolemic drugs on plasma fibrinogen concentration, six groups of subjects with primary hypercholesterolemia have been put on treatment with diet alone or diet plus fenofibrate (100 mg t.i.d.), slow release bezafibrate (400 mg once a day), gemfibrozil (600 mg b.i.d.), simvastatin (20 mg once a day) or pravastatin (20 mg once a day) respectively. After 1 month of therapy, plasma fibrinogen significantly decreased by 9% and 15% in fenofibrate and bezafibrate groups respectively and increased by 19% in gemfibrozil treated patients. After 4 months of therapy the changes were -16% with fenofibrate, -10% with bezafibrate and +20% with gemfibrozil. No significant changes were observed in patients treated with diet alone, simvastatin or pravastatin. The fibrinogen lowering effect of fenofibrate and bezafibrate does not seem to be related to the hypolipidemic activity of the drugs.

摘要

为了评估降胆固醇药物对血浆纤维蛋白原浓度的影响,六组原发性高胆固醇血症患者分别接受单纯饮食治疗或饮食加非诺贝特(每日三次,每次100毫克)、缓释苯扎贝特(每日一次,400毫克)、吉非贝齐(每日两次,每次600毫克)、辛伐他汀(每日一次,20毫克)或普伐他汀(每日一次,20毫克)治疗。治疗1个月后,非诺贝特组和苯扎贝特组的血浆纤维蛋白原分别显著下降了9%和15%,而吉非贝齐治疗的患者中纤维蛋白原增加了19%。治疗4个月后,非诺贝特组的变化为-16%,苯扎贝特组为-10%,吉非贝齐组为+20%。单纯饮食治疗、辛伐他汀或普伐他汀治疗的患者未观察到显著变化。非诺贝特和苯扎贝特降低纤维蛋白原的作用似乎与药物的降血脂活性无关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验